Beta-Cell Fragility As a Common Underlying Risk Factor in Type 1 and Type 2 Diabetes

This abstract has open access
Abstract Summary

Type 1 and type 2 diabetes are distinct clinical entities primarily driven by autoimmunity and metabolic dysfunction, respectively. However, there is a growing appreciation that they may share an etiopathological factor, namely the role of variation in beta-cell sensitivity to stress factors. Increased sensitivity increases the risk of beta-cell death or insulin secretion dysfunction. The beta-cell fragility model proposes that this variation contributes to the risk of developing either type 1 or type 2 diabetes, in the presence of immunological and/or metabolic stress factors. Therapeutics that increase the resistance of beta cells to these factors and decreasing fragility may constitute a new class of anti-diabetogenics, with potential use across both diseases.

Submission ID :
IDS63257
Submission Type
Abstract Topics

Abstracts With Same Type

Submission ID
Submission Title
Submission Topic
Submission Type
Primary Author
IDS82290
Invited
Invited
Professor Jay Skyler
IDS71294
Invited
Invited
Dr Sarah Richardson
IDS71310
Invited
Invited
Dr Richard Oram
IDS20295
Invited
Invited
Dr Helena Elding Larsson
9 visits

KEY DATES

Event dates:
Thursday 25 October - Monday 29 October 2018

Abstract submission deadline:
Monday 14 May 2018

Abstract notification:
July 2018

Early registration deadline:
Monday 3 September 2018

Registration deadline:
Monday 15 October 2018

Contact
British Society for Immunology
+44 (0)20 3019 5901
congress@immunology.org